A perspective on the ESVEM trial and current knowledge: catheter ablation for ventricular tachyarrhythmias.
Although an effective and potentially curative technique for treating idiopathic ventricular tachycardia, map-guided transcatheter radiofrequency ablation is far from optimal for ventricular tachyarrhythmias in patients with advanced ischemic or other types of organic heart disease. First, this technique can be applied only to a minority of patients with structural heart disease, who can tolerate relatively long episodes of induced ventricular tachycardia necessary for mapping and successful ablation. Second, the success rate is lower and recurrence higher in patients with organic heart disease. Finally, for patients who lose consciousness during tachycardia or who present with prehospital cardiac arrest, transcatheter radiofrequency ablation is inappropriate as definitive treatment. At best, it is palliative and may be used to suppress relatively slow, frequent, or incessant ventricular tachycardias but does not obviate the need for other therapies such as cardioverter-defibrillator implantation or antiarrhythmic drug therapy.
Garan
H
H
Cardiac Unit, Massachusetts General Hospital, Boston, MA 02114, USA.
D017115:Catheter Ablation; D002986:Clinical Trials as Topic; D004562:Electrocardiography; D006801:Humans; D017180:Tachycardia, Ventricular / Q000601:surgery*